Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Overview of attention for article published in Frontiers in oncology, October 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

So far, Altmetric has seen 1 news story.

Summary CDX-0158 is an example of a pipeline product that is underappreciated. Shares of Celldex Therapeutics trade at a…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.